Drug
Arbaclofen clinical trials
Also written STX209 and OS440.
- studies test it
- 21
- open now
- 2
- in phase 3
- 11
- first study started
- 2008
Keep track of what changes. Save the arbaclofen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- AERT
- 5
Studies by the year they started
20 studies that test it; most in 2011 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 8
- Phase 3
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 6
Seaside Therapeutics, Inc. (9) · RVL Pharmaceuticals, Inc. (6) · Clinical Research Associates, LLC (1) · Holland Bloorview Kids Rehabilitation Hospital (1) · Celso Arango, MD, PhD (1) · Timothy Roberts (1) · Hospital General Universitario Gregorio Marañon (1) · Gonzalez-Heydrich, Joseph, M.D. (1)
Studies
Open first, then newest update. How each study uses arbaclofen is read from its arms, and is right about nine times in ten.
Testing it · 21
- Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With thRecruitingPhase 3Hospital General Universitario Gregorio MarañonNCT07655115Written as Arbaclofen
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple SclerosisNot yet recruitingPhase 3RVL Pharmaceuticals, Inc.NCT05179577Written as Arbaclofen
- Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)CompletedPhase 2Holland Bloorview Kids Rehabilitation HospitalNCT03887676Written as Arbaclofen
- Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 DeletionActive, not recruitingPhase 2Clinical Research Associates, LLCNCT04271332Written as Arbaclofen
- Arbaclofen in Children and Adolescents With ASDCompletedPhase 2Celso Arango, MD, PhDNCT03682978Written as Arbaclofen
- A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MSCompletedPhase 3RVL Pharmaceuticals, Inc.NCT03319732Written as Arbaclofen
- A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSCompletedPhase 3RVL Pharmaceuticals, Inc.NCT03290131Written as Arbaclofen
- To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MSWithdrawnPhase 3RVL Pharmaceuticals, Inc.NCT02869425Written as arbaclofen ER Tablets
- One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With SpasticityCompletedPhase 3RVL Pharmaceuticals, Inc.NCT01844232Written as arbaclofen
- Efficacy Study of Arbaclofen to Treat Spasticity in Multiple SclerosisCompletedPhase 3RVL Pharmaceuticals, Inc.NCT01743651Written as arbaclofen
- MEG Study of Acute STX209 Effects in ASDCompletedEarly Phase 1Timothy RobertsNCT02278328Written as STX209 (15mg)
- TMS Measures of Plasticity and Excitatory/Inhibitory Ratio as Biomarkers: R-baclofen Effects in Normal VolunteersTerminatedPhase 1Gonzalez-Heydrich, Joseph, M.D.NCT01172509Written as R-baclofen
- Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X SyndromeCompletedPhase 3Seaside Therapeutics, Inc.NCT01325220Written as arbaclofen
- Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X SyndromeCompletedPhase 3Seaside Therapeutics, Inc.NCT01282268Written as arbaclofen
- Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum DisordersCompletedPhase 2Seaside Therapeutics, Inc.NCT01288716Written as Arbaclofen
- Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum DisordersTerminatedPhase 3Seaside Therapeutics, Inc.NCT01706523Written as STX209 (arbaclofen)
- An Open Label Extension Study in Subjects With Fragile X SyndromeTerminatedPhase 3Seaside Therapeutics, Inc.NCT01555333Written as arbaclofen
- Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum DisordersCompletedPhase 2Seaside Therapeutics, Inc.NCT00846547Written as Arbaclofen
- Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X SyndromeCompletedPhase 2Seaside Therapeutics, Inc.NCT00788073Written as STX209
- An Open Label Extension Study of STX209 in Subjects With Fragile X SyndromeTerminatedPhase 2Seaside Therapeutics, Inc.NCT01013480Written as Arbaclofen
Codes
What other systems call arbaclofen · ClinicalTrials.gg INT017427
- UNII (FDA) NYU6UTW25BARBACLOFENConfirmed FDA, Wikidata
- Wikidata Q27074844arbaclofenConfirmed FDA, Wikidata
- NCI Thesaurus C90890ArbaclofenOne source FDA
- DrugBank DB08891One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NYU6UTW25B | ARBACLOFEN | Confirmed FDA, Wikidata |
| Wikidata | Q27074844 | arbaclofen | Confirmed FDA, Wikidata |
| NCI Thesaurus | C90890 | Arbaclofen | One source FDA |
| DrugBank | DB08891 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.